Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the Korean Intellectual Property Office (KIPO) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™.
The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches.
The KIPO issued a prior notice of allowance in December 2020.
https://finance.yahoo.com/news/nutriband-inc-issued-full-patent-123000159.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.